Tarsus Pharmaceuticals, Inc. (TARS)
80.28
+3.39
(+4.41%)
USD |
NASDAQ |
Nov 13, 16:00
80.40
+0.12
(+0.15%)
After-Hours: 19:59
Tarsus Pharmaceuticals Debt to Equity Ratio : 0.8523 for Sept. 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.8523 |
| June 30, 2026 | 0.2557 |
| March 31, 2026 | 0.2541 |
| December 31, 2025 | 0.2418 |
| September 30, 2025 | 0.2462 |
| June 30, 2025 | 0.2178 |
| March 31, 2025 | 0.2113 |
| December 31, 2024 | 0.3227 |
| September 30, 2024 | 0.3046 |
| June 30, 2024 | 0.2862 |
| March 31, 2024 | 0.1109 |
| December 31, 2023 | 0.1611 |
| September 30, 2023 | 0.141 |
| June 30, 2023 | 0.1695 |
| Date | Value |
|---|---|
| March 31, 2023 | 0.1454 |
| December 31, 2022 | 0.1048 |
| September 30, 2022 | 0.0992 |
| June 30, 2022 | 0.091 |
| March 31, 2022 | 0.1357 |
| December 31, 2021 | 0.0072 |
| September 30, 2021 | 0.0072 |
| June 30, 2021 | 0.0033 |
| March 31, 2021 | 0.0037 |
| December 31, 2020 | 0.005 |
| September 30, 2020 | 0.0096 |
| June 30, 2020 | 0.0163 |
| March 31, 2020 | |
| December 31, 2019 | 0.0029 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Bristol Myers Squibb Co. | 1.915 |
| Amneal Pharmaceuticals, Inc. | 6.180 |
| Harmony Biosciences Holdings, Inc. | 0.2175 |
| ANI Pharmaceuticals, Inc. | 0.9531 |
| Corcept Therapeutics, Inc. | 0.0108 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 505.50M |
| Total Liabilities (Quarterly) | 401.47M |
| Shareholders Equity (Quarterly) | 104.03M |
| Current Ratio | 1.961 |
| Net Debt Paydown Yield | -0.08% |